Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Date:10/26/2007

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207).

In vitro data showed significant (p<0.001) synergistic growth inhibition of prostate cancer cells with combinations of docetaxel and SF1126, as well as synergistic growth inhibition of brain cancer cells with combinations of doxorubicin and SF1126. In addition, SF1126 and rapamycin showed excellent growth inhibition synergies across all prostate, renal and non-small cell lung cancer cell lines. Simultaneous dosing of SF1126 with docetaxel in a prostate xenograft model exhibited slightly improved tumor response time versus administering SF1126 prior to docetaxel administration. In this same xenograft model, using very large tumors, it was shown that SF1126 in combination with docetaxel gave significantly greater tumor regression than did docetaxel alone (p<0.05). SF1126 as a single agent showed significant tumor growth inhibition relative to the control group (73% inhibition, p<0.01) in this model as well.

"These data support that our lead compound, SF1126, is active as a single agent and in synergy with a growing list of standard chemotherapy agents," said Edward Jacobs, Semafore's president and chief executive officer. "This provides us with a pathway to clinical development in addition to our current phase I clinical trial in patients with solid tumors. We expect to complete our phase I clinical trial in the second quarter of 2008 and then evaluate SF1126 in additional trials, both as a single and combined therapy."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus--cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PENN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's website at http://www.semaforepharma.com.

Contact: David Schull or Timothy Engel

Russo Partners, LLC

212.845.4271

david.schull@russopartnersllc.com

timothy.engel@russopartnersllc.com


'/>"/>
SOURCE Semafore Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
5. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
9. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
Breaking Medicine News(10 mins):